Total Payments
$435,150
2024 Payments
$152,294
Companies
19
Transactions
338
Medicare Patients
588
Medicare Billing
$69,978
Payment Breakdown by Category
Consulting$228,683 (52.6%)
Other$146,073 (33.6%)
Travel$45,659 (10.5%)
Research$7,615 (1.7%)
Food & Beverage$6,956 (1.6%)
Education$164.74 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $228,683 | 97 | 52.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $138,693 | 40 | 31.9% |
| Travel and Lodging | $45,659 | 85 | 10.5% |
| Unspecified | $7,615 | 10 | 1.7% |
| Honoraria | $7,380 | 2 | 1.7% |
| Food and Beverage | $6,956 | 102 | 1.6% |
| Education | $164.74 | 2 | 0.0% |
Payments by Type
General
$427,535
328 transactions
Research
$7,615
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $138,003 | 100 | $0 (2024) |
| Janssen Biotech, Inc. | $63,263 | 55 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $52,960 | 37 | $0 (2024) |
| PFIZER INC. | $43,676 | 40 | $0 (2024) |
| Celltrion USA Inc. | $35,577 | 24 | $0 (2024) |
| Janssen Research & Development, LLC | $18,875 | 12 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $17,990 | 19 | $0 (2022) |
| SANOFI US SERVICES INC. | $11,700 | 1 | $0 (2024) |
| Eli Lilly and Company | $11,455 | 3 | $0 (2024) |
| Ferring Pharmaceuticals Inc. | $8,010 | 13 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $152,294 | 97 | Celltrion USA Inc. ($35,577) |
| 2023 | $100,622 | 63 | AbbVie Inc. ($57,143) |
| 2022 | $44,653 | 46 | ABBVIE INC. ($23,024) |
| 2021 | $11,462 | 9 | AbbVie Inc. ($6,400) |
| 2020 | $14,599 | 11 | Janssen Biotech, Inc. ($6,051) |
| 2019 | $29,109 | 36 | Takeda Pharmaceuticals U.S.A., Inc. ($10,135) |
| 2018 | $20,598 | 26 | PFIZER INC. ($5,920) |
| 2017 | $61,812 | 50 | PFIZER INC. ($15,048) |
All Payment Transactions
338 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $2,125.00 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Travel and Lodging | In-kind items and services | $780.67 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Immunology | ||||||
| 12/16/2024 | ABBVIE INC. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,500.00 | General |
| 12/09/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,300.00 | General |
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $38.42 | General |
| Category: Immunology | ||||||
| 11/23/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,675.00 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Janssen Biotech, Inc. | STELARA (Biological), TREMFYA, REMICADE | Consulting Fee | Cash or cash equivalent | $1,275.00 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $120.59 | General |
| Category: Immunology | ||||||
| 11/15/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Travel and Lodging | In-kind items and services | $102.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/15/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Travel and Lodging | In-kind items and services | $46.57 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/14/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Consulting Fee | Cash or cash equivalent | $13,040.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/14/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Travel and Lodging | In-kind items and services | $204.21 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/14/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Education | In-kind items and services | $150.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/14/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Food and Beverage | In-kind items and services | $32.13 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/14/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Food and Beverage | In-kind items and services | $27.13 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/14/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Travel and Lodging | In-kind items and services | $3.23 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/13/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Travel and Lodging | In-kind items and services | $203.34 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/13/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Food and Beverage | In-kind items and services | $69.67 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/13/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Food and Beverage | In-kind items and services | $34.13 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/13/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Travel and Lodging | In-kind items and services | $2.49 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/12/2024 | Eli Lilly and Company | OMVOH (Drug) | Consulting Fee | Cash or cash equivalent | $4,800.00 | General |
| Category: Immunology | ||||||
| 11/12/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Travel and Lodging | In-kind items and services | $203.20 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/12/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Food and Beverage | In-kind items and services | $58.26 | General |
| Category: GASTROENTEROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| THE EFFECT OF DULAGLUTIDE ON MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES - RESEARCHING CARDIOVASCULAR EVENTS WITH A WEEKLY INCRETIN IN DIABETES - REWIND | Eli Lilly and Company | $6,655 | 2 |
| NN9068-4148 | Novo Nordisk AS | $605.00 | 6 |
| NN9931-4296 | Novo Nordisk AS | $300.00 | 1 |
| NN9068-4228 | Novo Nordisk AS | $55.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 163 | 180 | $111,423 | $18,881 |
| 2022 | 7 | 188 | 220 | $135,587 | $24,312 |
| 2021 | 4 | 117 | 151 | $85,510 | $16,467 |
| 2020 | 5 | 120 | 134 | $56,172 | $10,318 |
Total Patients
588
Total Services
685
Medicare Billing
$69,978
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 48 | 60 | $28,860 | $6,256 | 21.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 28 | 28 | $31,836 | $3,251 | 10.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 40 | 45 | $14,670 | $3,059 | 20.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 13 | 13 | $17,511 | $2,860 | 16.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 18 | 18 | $7,938 | $1,982 | 25.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 16 | 16 | $10,608 | $1,474 | 13.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 56 | 80 | $38,480 | $9,079 | 23.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 17 | 17 | $22,899 | $3,746 | 16.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 32 | 32 | $36,384 | $3,702 | 10.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 35 | 41 | $13,366 | $2,930 | 21.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 21 | 23 | $10,143 | $2,664 | 26.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 16 | 16 | $10,608 | $1,501 | 14.1% |
| 45331 | Biopsy of lower large bowel using a flexible endoscope | Facility | 2022 | 11 | 11 | $3,707 | $689.39 | 18.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 24 | 43 | $20,570 | $5,310 | 25.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 49 | 64 | $20,600 | $5,115 | 24.8% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 32 | 32 | $36,384 | $4,743 | 13.0% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 12 | 12 | $7,956 | $1,299 | 16.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 43 | 57 | $16,656 | $3,803 | 22.8% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 22 | 22 | $25,014 | $2,972 | 11.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 21 | 21 | $9,534 | $2,523 | 26.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 18 | 18 | $4,680 | $956.59 | 20.4% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2020 | 16 | 16 | $288.00 | $63.79 | 22.1% |
About Dr. Adam Cheifetz, M.D
Dr. Adam Cheifetz, M.D is a Gastroenterology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1811934417.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adam Cheifetz, M.D has received a total of $435,150 in payments from pharmaceutical and medical device companies, with $152,294 received in 2024. These payments were reported across 338 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($228,683).
As a Medicare-enrolled provider, Cheifetz has provided services to 588 Medicare beneficiaries, totaling 685 services with total Medicare billing of $69,978. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Boston, MA
- Active Since 06/01/2006
- Last Updated 04/25/2011
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1811934417
Products in Payments
- ZYMFENTRA (Biological) $35,577
- TREMFYA (Drug) $32,555
- STELARA (Biological) $30,708
- XELJANZ (Drug) $30,026
- RINVOQ (Biological) $25,333
- INVOKANA (Drug) $18,875
- SKYRIZI (Biological) $17,014
- Humira (Biological) $15,828
- Entyvio (Biological) $13,190
- PREPOPIK (Drug) $8,010
- TRULICITY (Drug) $6,655
- FERAHEME (Drug) $6,600
- OMVOH (Drug) $4,800
- SIMPONI ARIA (Biological) $4,739
- ZEPOSIA (Drug) $3,375
- ENTYVIO (Biological) $2,625
- HUMIRA (Biological) $1,600
- RENFLEXIS (Biological) $1,440
- Xultophy 100/3.6 (Drug) $715.00
- Trulance (Drug) $14.74
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Boston
Dr. Hiroyuki Aihara, M.d, M.D
Gastroenterology — Payments: $1.0M
Gastroenterology $1.0M
Dr. Ramnik Xavier, Md, MD
Gastroenterology — Payments: $518,235
Gastroenterology $518,235
Fredric Gordon, M.d, M.D
Gastroenterology — Payments: $280,379
Gastroenterology $280,379
Dr. Tyler Berzin, Md, MD
Gastroenterology — Payments: $230,903
Gastroenterology $230,903
Dr. Douglas Pleskow, M.d, M.D
Gastroenterology — Payments: $170,196
Gastroenterology $170,196
Christopher Thompson, M.d., M.s, M.D., M.S
Gastroenterology — Payments: $167,136
Gastroenterology $167,136